Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas De Raedt

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Genes, Chromosomes & Cancer|October 12, 2011
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumorsEline Beert, Hilde Brems, Bruno Daniëls, et al.
Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Cancer Cell|September 13, 2011
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumorsThomas De Raedt, Zandra Walton, Jessica L Yecies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse ModelsSara Ortega-Bertran, Juana Fernández-Rodríguez, Miriam Magallón-Lorenz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesisArmelle Luscan, Ghjuvan'ghjacumu Shackleford, Julien Masliah-Planchon, et al.
Nature Communications|August 16, 2022
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastomaShannon Coy, Shu Wang, Sylwia A Stopka, et al.
Cancer Cell|July 4, 2009
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesisLauren T McGillicuddy, Jody A Fromm, Pablo E Hollstein, et al.
American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.
Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
A longitudinal single-cell and spatial multiomic atlas of pediatric high-grade gliomaJonathan H Sussman, Derek A Oldridge, Wenbao Yu, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Genes, Chromosomes & Cancer|October 12, 2011
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumorsEline Beert, Hilde Brems, Bruno Daniëls, et al.
Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Cancer Cell|September 13, 2011
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumorsThomas De Raedt, Zandra Walton, Jessica L Yecies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse ModelsSara Ortega-Bertran, Juana Fernández-Rodríguez, Miriam Magallón-Lorenz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesisArmelle Luscan, Ghjuvan'ghjacumu Shackleford, Julien Masliah-Planchon, et al.
Nature Communications|August 16, 2022
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastomaShannon Coy, Shu Wang, Sylwia A Stopka, et al.
Cancer Cell|July 4, 2009
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesisLauren T McGillicuddy, Jody A Fromm, Pablo E Hollstein, et al.
American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.
Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
A longitudinal single-cell and spatial multiomic atlas of pediatric high-grade gliomaJonathan H Sussman, Derek A Oldridge, Wenbao Yu, et al.
Pageof 4